Navigation Links
AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate
Date:12/15/2009

WASHINGTON, Dec. 15 /PRNewswire-USNewswire/ -- Today's New York Times article by Kevin Sack, "Plan for Kidney Drugs Spurs Division," illustrates an internal renal community reimbursement debate that may result in kidney patients continuing to be deprived of their life-saving immunosuppressive medications beyond the current 36-month Medicare program limit.

As Congress is poised to approve this urgent transplant patient coverage to preserve the lives of transplant kidney recipients, behind-the-scenes debate continues within the renal community regarding how dialysis should be reimbursed. The American Society of Transplantation (AST) believes strongly that dialysis reimbursement, while important, should not hold hostage a bill that would provide thousands of kidney transplant patients their desperately needed and life-saving immunosuppressant medications.

AST President, Dr. Joren Madsen, stated this morning, "I applaud the New York Times for drawing attention to an urgent patient care issue which should not fall victim to politics as usual." Transplant patient immunosuppressive drug coverage has been AST's #1 Public Policy Issue for more than a decade. As this morning's New York Times article states, "It is pound foolish" to pay for a patient's organ transplant and then only give them a 36-month supply of the drugs they need to maintain their life-saving donor organ for the remainder of their life.

About AST

The American Society of Transplantation is an international organization of transplant professionals dedicated to advancing the field of transplantation through the promotion of research, education, advocacy, and organ donation to improve patient care. The Society comprises more than 3,100 transplant physicians, surgeons and allied health professionals.

For information about AST, visit www.a-s-t.org.


    CONTACT: Beth Drost at 215.884.6499
    beth@comsolutionsgroup.com

SOURCE The American Society of Transplantation


'/>"/>
SOURCE The American Society of Transplantation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ACC Concerned Over Reporting of Biomonitoring Results
2. Methodist Dallas Medical Center First in Metroplex to Perform Kidney Transplant on HIV Positive Patient
3. FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
4. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
5. FDA Approves New Treatment for Advanced Form of Kidney Cancer
6. Satellite Healthcare Tees Up With the National Kidney Foundation in Santa Cruz, CA
7. Study Suggests that NGAL Identifies Acute Kidney Injury Early in ICU Patients
8. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
9. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
10. WORLDS First Robotic Assisted Kidney Transplant Performed at Saint Barnabas Medical Center
11. Living Donor Kidney Transplants Using Alemtuzumab Pre-Conditioning and Tacrolimus Monotherapy: Long-Term Safety and Efficacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Boston Scientific Corporation (NYSE: BSX ) ... assets and capabilities of the Neovasc, Inc., (NASDAQ: ... as well as a 15% equity stake in Neovasc, ... Neovasc advanced biological tissue business makes elements used in ... System. * Upon completion of the transaction, the ...
(Date:12/2/2016)... , Dec. 2, 2016 Lianluo ... Smart" or "the Company") which develops, markets and ... in China and international ... Disease Diagnosis and Treatment New Progress Forum, co-hosted ... Guangdong Province , Guangdong Provincial People,s ...
(Date:12/2/2016)... 2016 On Thursday, the NASDAQ Composite ... while the Dow Jones Industrial Average managed to stay in ... markets, which prompted Stock-callers this morning to look at the ... NUVA ), Smith & Nephew PLC (NYSE: ... and Cesca Therapeutics Inc. (NASDAQ: KOOL ). You ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... , ... Sourced from the Isbre Springs beneath the 5,000 year old Hardanger ... of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent taste ... several ShopRite and FoodTown stores in NJ and received rave comments from consumers. , ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... ... ‘Tis the season for giving! Today, 20 creative teams across the nation ... the Drug Enforcement Administration as part of the National Red Ribbon Week Photo Contest. ... decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be Drug Free,” ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard ... 75, an annual ranking and recognition of the largest closely held companies headquartered ... ranked from 2008-2016. In addition, Standard Process was awarded the Talent Award for ...
(Date:11/30/2016)... ... 2016 , ... The Cronovo Smartwatch, the first on the ... at an affordable price, is now available on the crowdfunding website Kickstarter ... changer” when it comes to the smartwatch. , "With Cronovo, we’ve combined the ...
Breaking Medicine News(10 mins):